Heron Therapeutics Inc vs The Coca-Cola Co K — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while The Coca-Cola Co K trades at $87.44 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 5552.6× Heron Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and The Coca-Cola Co K for 154 Days on average.
| HRTX | KO | |
|---|---|---|
Market Cap | $68.01M | $377.63B |
Volume | 1,891,941 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $91.99 |
52-Week Low | $0.27 | $66.37 |
Typical Hold Time | 35 Days | 154 Days |
Enterprise Value | $174.75M | $404.81B |
Dividend Yield | — | 2.42% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations. KO maintains robust profitability with 61.89% gross margins and 28.56% net income margins, supported by steady revenue growth and a dominant market position.
The stock presents a compelling dividend opportunity with 64 consecutive years of increases, though technical indicators suggest near-term pressure. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential. Key risks include regional demand divergence and high valuation multiples that may limit short-term appreciation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →